国产成人三级网址在线看_日韩高清在线毛片_精品国内自产拍在线观看尤物_欧美精品 亚洲日韩_成人黄色影片在线看_国产一区二区播放_国产午夜理论最新电影_日本伊人久久综合_亚洲国产网站视频在线播放_日韩人妻系列无码专区

細(xì)胞程序性死亡蛋白1配體1(PDL1)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,寬范圍)

Wide-range ELISA Kit for Programmed Cell Death Protein 1 Ligand 1 (PDL1)

CD274; PDCD1LG1; B7-H; B7H1; PD-L1; PDCD1L1; PDCD1-LG1; Programed Death Ligand 1

  • 細(xì)胞程序性死亡蛋白1配體1(PDL1)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,寬范圍) 產(chǎn)品包裝(模擬)
  • 細(xì)胞程序性死亡蛋白1配體1(PDL1)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,寬范圍) 產(chǎn)品包裝(模擬)
  • 細(xì)胞程序性死亡蛋白1配體1(PDL1)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,寬范圍) 實(shí)驗(yàn)結(jié)果圖
  • WEA788Hu.jpg 標(biāo)準(zhǔn)曲線圖
  • Certificate 通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證

特異性

本試劑盒用于檢測(cè)細(xì)胞程序性死亡蛋白1配體1(PDL1)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,寬范圍),經(jīng)檢測(cè)與其它相似物質(zhì)無(wú)明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來(lái)源的限制,不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè),因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。

精密度

精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差:取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次,分別計(jì)算不同濃度樣本的平均值及SD值。
批間差:選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定,每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次,分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差: CV<10%
批間差: CV<12%

穩(wěn)定性

經(jīng)測(cè)定,試劑盒在有效期內(nèi)按推薦溫度保存,其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響,實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致,尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來(lái)進(jìn)行操作可減少人為誤差。

實(shí)驗(yàn)流程

1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本的準(zhǔn)備;
2. 加樣(標(biāo)準(zhǔn)品及樣本)100µL,37°C孵育1小時(shí);
3. 吸棄,加檢測(cè)溶液A100µL,37°C孵育1小時(shí);
4. 洗板3次;
5. 加檢測(cè)溶液B100µL,37°C孵育30分鐘;
6. 洗板5次;
7. 加TMB底物90µL,37°C孵育10-20分鐘;
8. 加終止液50µL,立即450nm讀數(shù)。

實(shí)驗(yàn)原理

將細(xì)胞程序性死亡蛋白1配體1(PDL1)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,寬范圍)抗體包被于96孔微孔板中,制成固相載體,向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本,其中的細(xì)胞程序性死亡蛋白1配體1(PDL1)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,寬范圍)與連接于固相載體上的抗體結(jié)合,然后加入生物素化的細(xì)胞程序性死亡蛋白1配體1(PDL1)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,寬范圍)抗體,將未結(jié)合的生物素化抗體洗凈后,加入HRP標(biāo)記的親和素,再次徹底洗滌后加入TMB底物顯色。TMB在過(guò)氧化物酶的催化下轉(zhuǎn)化成藍(lán)色,并在酸的作用下轉(zhuǎn)化成最終的黃色。顏色的深淺和樣品中的細(xì)胞程序性死亡蛋白1配體1(PDL1)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,寬范圍)呈正相關(guān)。用酶標(biāo)儀在450nm波長(zhǎng)下測(cè)定吸光度(O.D.值),計(jì)算樣品濃度。

相關(guān)產(chǎn)品

編號(hào) 適用物種:Homo sapiens (Human,人) 應(yīng)用(僅供研究使用,不用于臨床診斷!)
RPA788Hu02 細(xì)胞程序性死亡蛋白1配體1(PDL1)重組蛋白 Positive Control; Immunogen; SDS-PAGE; WB.
RPA788Hu01 細(xì)胞程序性死亡蛋白1配體1(PDL1)重組蛋白 Positive Control; Immunogen; SDS-PAGE; WB.
APA788Hu61 細(xì)胞程序性死亡蛋白1配體1(PDL1)活性蛋白 Cell?culture;?Activity?Assays.
EPA788Hu61 細(xì)胞程序性死亡蛋白1配體1(PDL1)真核蛋白 Positive Control; Immunogen; SDS-PAGE; WB.
PAA788Hu01 細(xì)胞程序性死亡蛋白1配體1(PDL1)多克隆抗體 WB; ICC/IF
FAA788Hu01 抗細(xì)胞程序性死亡蛋白1配體1(PDL1)多克隆抗體 Flow cytometry.
FAA788Hu41 抗細(xì)胞程序性死亡蛋白1配體1(PDL1)多克隆抗體(藻紅素標(biāo)記) Flow cytometry.
FAA788Hu51 抗細(xì)胞程序性死亡蛋白1配體1(PDL1)多克隆抗體(別藻藍(lán)蛋白標(biāo)記) Flow cytometry.
FAA788Hu81 抗細(xì)胞程序性死亡蛋白1配體1(PDL1)多克隆抗體(異硫氰酸熒光素標(biāo)記) Flow cytometry.
MAA788Hu28 細(xì)胞程序性死亡蛋白1配體1(PDL1)單克隆抗體 WB; IHC; ICC; IP.
MAA788Hu22 細(xì)胞程序性死亡蛋白1配體1(PDL1)單克隆抗體 WB; IHC; ICC; IP.
RAA788Hu22 細(xì)胞程序性死亡蛋白1配體1(PDL1)重組抗體 WB; IF; ICC; IHC; IP; FCM.
MAA788Hu21 細(xì)胞程序性死亡蛋白1配體1(PDL1)單克隆抗體 WB; IHC; ICC; IP.
MAA788Hu23 細(xì)胞程序性死亡蛋白1配體1(PDL1)單克隆抗體 WB; IHC; ICC; IP.
MAA788Hu24 細(xì)胞程序性死亡蛋白1配體1(PDL1)單克隆抗體 WB; IHC; ICC; IP.
MAA788Hu25 細(xì)胞程序性死亡蛋白1配體1(PDL1)單克隆抗體 WB; IHC; ICC; IP.
MAA788Hu27 細(xì)胞程序性死亡蛋白1配體1(PDL1)單克隆抗體 WB; IHC; ICC; IP.
MAA788Hu29 細(xì)胞程序性死亡蛋白1配體1(PDL1)單克隆抗體 WB; IHC; ICC; IP.
MAA788Hu26 細(xì)胞程序性死亡蛋白1配體1(PDL1)單克隆抗體 WB; IHC; ICC; IP.
RAA788Hu21 細(xì)胞程序性死亡蛋白1配體1(PDL1)重組抗體 WB; IF; ICC; IHC; IP; FCM.
LAA788Hu72 細(xì)胞程序性死亡蛋白1配體1(PDL1)單克隆抗體(生物素標(biāo)記) WB; IHC; ICC.
FAA788Hu82 抗細(xì)胞程序性死亡蛋白1配體1(PDL1)單克隆抗體(異硫氰酸熒光素標(biāo)記) Flow cytometry.
WEA788Hu 細(xì)胞程序性死亡蛋白1配體1(PDL1)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,寬范圍) Enzyme-linked immunosorbent assay for Antigen Detection.
SEA788Hu 細(xì)胞程序性死亡蛋白1配體1(PDL1)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) Enzyme-linked immunosorbent assay for Antigen Detection.
SCA788Hu 細(xì)胞程序性死亡蛋白1配體1(PDL1)檢測(cè)試劑盒(化學(xué)發(fā)光免疫分析法) Chemiluminescent immunoassay for Antigen Detection.
LMA788Hu 細(xì)胞程序性死亡蛋白1配體1(PDL1)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) FLIA Kit for Antigen Detection.
PSA788Hu01 細(xì)胞程序性死亡蛋白1配體1(PDL1)抗體對(duì) ELISA; CLIA; ELISPOT; Luminex; Immunochromatography and other Immunoassays.
KSA788Hu01 細(xì)胞程序性死亡蛋白1配體1(PDL1)檢測(cè)試劑盒DIY材料(酶聯(lián)免疫吸附試驗(yàn)法) Main materials for "Do It (ELISA Kit) Yourself".

參考文獻(xiàn)

雜志 參考文獻(xiàn)
Chinese Journal of Cancer Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications [NCBI: PMC3937742]
Leukemia.? High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial. [Pubmed:24732592]
Diabetes?Metab Res Rev. PD‐L1 gene polymorphisms and low serum level of PD‐L1 protein are associated to type 1 diabetes in Chile [Pubmed:24816853]
Lancet Haematol Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study [PubMed: 26686046]
Eur J Cancer.? High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis. [Pubmed:27039170]
Journal of Cancer Research and Clinical Oncology Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer [article:10.1007]
Journal of Hematology & Oncology PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma [pubmed:27737703]
Lung Cancer. High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer. [pubmed:28212990]
Oncotarget Soluble?programmed?death-ligand?1?(sPDL1) and?neutrophil-to-lymphocyte?ratio?(NLR)?predictssurvival?in?advanced?biliary?tract?cancer?patients?treated?with palliative chemotherapy. [pubmed:27780932]
Oncotarget High?post-treatment?serum?levels?of?soluble?programmed?cell?death?ligand?1?predict?earlyrelapse?and?poor?prognosis?in?extranodal?NK/T?cell?lymphoma patients. [pubmed:27105512]
Oncotarget.? Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma [pubmed:27566569]
Cancer Immunol Immunother. Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy. [pubmed:28349165]
Leukemia Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients [leu2016385a]
Medicine Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy. [pubmed:28207525]
Allergology International? Inverse correlation of soluble programmed cell death-1 ligand-1 (sPD-L1) with eosinophil count and clinical severity in allergic rhinitis patients [pubmed:27617656]
Medicine Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy [PMC5319514]
American Journal of Respiratory and Critical Care Medicine Soluble Programed Death Receptor 1 Ligand (sPD-L1) in Pleural Fluid of Patients with Malignant Pleural Mesothelioma (MPM) [Pdf:10.1164]
Clinical Lung Cancer Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non–Small-cell Lung Cancer [Pubmed:29859759]
Journal of Rheumatology Increased levels of soluble programmed death ligand 1 associate with malignancy in patients with dermatomyositis [Pubmed:29419471]
Translational?Oncology High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma [Pubmed:29698935]
Immunology?Letters Increased levels of soluble co-stimulatory molecule PD-L1 (B7-H1) in the plasma of viraemic HIV-1+ individuals [Pubmed: 30236481]
Journal of?Cancer?Research?and?Clinical?Oncology Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma [Pubmed: 30267213]
Annals?of?Surgical?Oncology Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between?… [Pubmed: 30565045]
American Journal of Reproductive Immunology Identification of programmed cell death 1 and its ligand in the testicular tissue of mice [Pubmed: 30578744]
PLoS?One Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated?… [Pubmed: 30807610]
Endocrine Connections Elevated levels of soluble PD-L1 are associated with reduced recurrence in papillary thyroid cancer [Pubmed: 31252406]
Scientific Reports Prognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer [Pubmed: 31366979]
Critical Reviews in Oncology / Hematology The Clinical Significance of Soluble PD-1 and PD-L1 in Lung Cancer [Pubmed: 31675543]
PLoS One Clinical implications of APOBEC3A and 3B expression in patients with breast cancer [Pubmed: 32176735]
Cancers Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study [Pubmed: 32085544]
Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma [Pubmed: 32054467]
LIVER INTERNATIONAL The prognostic role of soluble transforming growth factor‐β and its correlation with soluble programmed death‐ligand 1 in biliary tract cancer [Pubmed: 32780918]
CANCER IMMUNOLOGY IMMUNOTHERAPY Prognostic impacts of tumoral expression and serum levels of PD-L1 and CTLA-4 in colorectal cancer patients [Pubmed: 32577816]
Soluble PD-L1: a potential immune marker for HIV-1 infection and virological failure [Pubmed: 32443313]
Cancer Immunol Immunother The clinical implication of soluble PD-L1 (sPD-L1) in patients with breast cancer and its biological function in regulating the function of T lymphocyte [33688997]
Acta Biochim Biophys Sin Prognostic prospect of soluble programmed cell death ligand-1 (sPD-L1) in cancer management [34180502]
EMBO J Microglial PD‐1 stimulation by astrocytic PD‐L1 suppresses neuroinflammation and Alzheimer's disease pathology [34825707]
Mol Pharm A Novel Small Cyclic Peptide-Based 68Ga-Radiotracer for Positron Emission Tomography Imaging of PD-L1 Expression in Tumors [34910492]
Mol Hum Reprod Macrophage Associated Immune Checkpoint CD47 Blocking Ameliorates Endometriosis [Pubmed:35404426]
Journal of Nanobiotechnology Microbial hydrogen “manufactory” for enhanced gas therapy and self-activated immunotherapy via reduced immune escape [Pubmed:35705974]
Medicina Assessment of the RANTES Level Correlation and Selected Inflammatory and Pro-Angiogenic Molecules Evaluation of Their Influence on CRC Clinical Features: A?… [Pubmed:35208526]
留言咨詢